Abstract: Objective To analyze the risk of the mouse nerve growth factor for injection in China in order to provide reference for clinical rational drug use. Methods The individual cases of adverse drug reactions reported in China adverse drug reaction (ADR) database between January 1, 2004 and October 31, 2019, domestic and foreign literature published from the inception of the library to February 29, 2020, and risk management measures taken in China were analyzed. Results and Conclusion It was found that this product should be used at the dosage stipulated in the specifications, clinicians should be alert to such adverse reactions as severe allergies, and that indications of special populations should be monitored. Drug manufacturers should assume more responsibility for adverse drug reaction monitoring and evaluation, improve the information collection channels of ADR, upgrade the analysis and evaluation of adverse drug reactions, update the information on safety in drug labels, and take the initiative to carry out post-market safety studies when necessary.

Key words: mouse nerve growth factor for injection, adverse drug reaction, risk, regulatory measures